-
Puluo Pharmaceutical Co., Ltd. and Shanghai Institute of Pharmaceutical Research Co., Ltd. to develop 1.1 new chemical drugs
Time of Update: 2015-06-09
Puluo Pharmaceutical (000739) announced in the evening of June 8 that in order to promote the company's business from APIs to pharmaceutical products, and then to innovative drugs, Zhejiang Jutai Phar
-
CDE Drug Evaluation Weekly Report (2015.5.24-2015.5.30)
Time of Update: 2015-06-08
In the review this week (2015.5.31-2015.6.6), a total of 123 drugs (calculated according to the acceptance number, the same below) have recently entered the review state, including 111 chemicals (7 ch
-
Analysis report on CDE drug review in May 2015
Time of Update: 2015-06-07
On May 27, 2015, the 20-year drug registration fee standard ushered in a significant change, shocking the entire drug circle Let's take a look at the last month before the price rise What did pharmace
-
Haizheng pharmaceutical 1.1 Alzheimer's treatment drug AD35 is expected to be approved clinically
Time of Update: 2015-06-05
According to the information on CFDA's website on June 5, the application status of Haizheng Pharmaceutical (600267 SH) 1.1 new chemical medicine ad-35 and ad-35 tablets changed to "certificate prepar
-
Bupropion sustained release tablets, a new depression drug of Huahai pharmaceutical, was approved by FDA
Time of Update: 2015-06-04
Huahai Pharmaceutical (600521) announced in the evening of June 4 that the company had received a notice from the U.S Food and Drug Administration (FDA) recently The Anda of bupropion sustained-releas
-
Jinsai Pharmaceutical Co., Ltd. is about to be approved for production of follicle stimulating hormone
Time of Update: 2015-06-04
According to the information on the website of CFDA on June 4, the processing status of recombinant human follicle stimulating hormone for injection of heavy biological products of Jinsai Pharmaceutic
-
CDE Drug Evaluation Weekly Report (2015.5.24-2015.5.30)
Time of Update: 2015-06-02
1 In the review of this week (2015.5.24-2015.5.30), 45 new drugs (calculated by acceptance number, excluding reexamination and supplementary application, the same below), including 1 Traditional Chine
-
Important progress in research of anti mers drugs by Jiang Shibo team of Fudan University
Time of Update: 2015-06-02
Since the first case of imported Middle East respiratory syndrome (mers) was diagnosed in China on May 28, all parties in China have shown great concern The good news is that Jiang Shibo, a scholar of
-
The first new Chinese medicine "Xiaoer Huanglong granule (Jingning)" for the treatment of ADHD in China is on the market
Time of Update: 2015-05-29
According to Chongqing Science and Technology Commission, the new traditional Chinese medicine "Xiaoer Huanglong granule (jingyining ®)" independently developed by Chongqing hilan Pharmaceutical Co.,
-
Flufenidone, a class 1.1 new drug of hainanhaiyao, is expected to obtain clinical approval in the second half of this year
Time of Update: 2015-05-28
A person from Hainan Haiyao (000566 SZ) company said in a conference call held by a securities firm that the company's class 1.1 new drug, flufenidone, is expected to obtain clinical approval in the s
-
Ceritinib, a Novartis ALK inhibitor, has been accepted by CDE
Time of Update: 2015-05-28
Ceratinib, an ALK inhibitor of Novartis, submitted a clinical application in China under the generic name of "seretinib", which was undertaken by CDE on May 22, 2015 and entered the evaluation center
-
A brief report on the application of new drugs in Fujian Province in 2014
Time of Update: 2015-05-27
According to the food and Drug Administration of Fujian Province, in 2014, the number of new drug applications in Fujian Province was 27 varieties, and the number of generic drug applications was 25 v
-
Rvx208, a new cardiovascular and cerebrovascular drug, is preparing for the third phase of clinical application
Time of Update: 2015-05-27
On the interactive platform, Highbury (002399 SZ) said that rvx208 is actively preparing for phase III clinical Insiders of the company said that this product is for the treatment of coronary arterios
-
CDE Drug Evaluation Weekly Report (2015.5.17-2015.5.24)
Time of Update: 2015-05-25
1 In the approval week (2015.5.17-2015.5.23), a total of 14 drugs (calculated according to the acceptance number, the same below) entered the approval stage, including 13 chemicals and 1 Traditional C
-
Yuheng Pharmaceutical Co., Ltd. and Wuxi Pharmaceutical Co., Ltd. signed a strategic cooperation on new chemical class 1.1 drugs
Time of Update: 2015-05-25
Apart from the three areas that we are good at, are there any plans to enter other disease areas?
-
CFDA approved zytiga for the treatment of metastatic castration resistant prostate cancer
Time of Update: 2015-05-22
[May 22, 2015, Beijing] - Xi'an Janssen Pharmaceutical Co., Ltd announced today that the State Food and drug administration has approved the drug zytiga, which is the combination of abitrone acetate a
-
R & D strength upgrading, Fosun Pharmaceutical Co acquisition of ambrx
Time of Update: 2015-05-22
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading pharmaceutical and health enterprise in China (hereinafter referred to as "Fosun Pharmaceutical" or "company"; Stock Code: 600196-sh, 02196-h
-
The research and development of bear bile powder in vitro by Shanghai Kaibao is expected to go further in the next year
Time of Update: 2015-05-21
Shanghai Kaibao (300039 SZ) insiders said that the key technology of cultivating bear bile powder in vitro has entered the critical period of pilot test, and it is expected to complete the kilogram le
-
The new drug artemethine maleate for the treatment of systemic lupus erythematosus was approved by Shanghai Pharmaceutical Research Institute
Time of Update: 2015-05-20
On May 20, it was learned from the Chinese Academy of Sciences that Zuo Jianping's research group and Li Ying's researcher of Shanghai Pharmaceutical Research Institute of the Academy spent 15 years t
-
Baiyunshan and huangtuyiyuan increase the research and development of traditional Chinese Medicine
Time of Update: 2015-05-20
On May 5, the national development and Reform Commission, together with the national health and Family Planning Commission, the Ministry of human resources and social security, issued the opinions on
